Platform & MSO Finance

Operators at every site must own revenue-protecting decisions before claims enter the system.

Buyers need infusion-specific RCM controls to validate acquisition financials.

Look for vendors that own the handoff between software automation and operator judgment.

Infusion billing's drug-cost and authorization complexity breaks general-purpose platforms.

Payer behavior, not internal operations, now drives infusion revenue loss.

Buyers must audit billing infrastructure, not just revenue, to value infusion practices correctly.

Margin, not revenue, determines whether an infusion practice survives.

Fragmented infusion RCM creates hidden revenue leaks that standard due diligence misses.

Payer policy shifts now pose bigger revenue risks than staffing for infusion platforms.

Structuring RCM functions by risk exposure, not centralization preference, prevents costly denials.